Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids

By Brooke Schuster, M. Junkin, S. Kashaf, I. Romero-Calvo, Kori Kirby, Jonathan Matthews, C. Weber, Andrey Rzhetsky, Kevin P. White, S. Tay. Nature Communications, 2020

348 citations recorded by the source corpus.

Three-dimensional (3D) cell culture technologies, such as organoids, are physiologically relevant models for basic and clinical applications. Automated microfluidics offers advantages in high-throughput and precision analysis of cells but is not yet compatible with organoids. Here, we present an automated, high-throughput, microfluidic 3D organoid culture and analysis system to facilitate preclinical research and personalized therapies. Our system provides combinatorial and dynamic drug treatments to hundreds of cultures and enables real-time analysis of organoids. We validate our system by performing individual, combinatorial, and sequential drug screens on human-derived pancreatic tumor organoids. We observe significant differences in the response of individual patient-based organoids to drug treatments and find that temporally-modified drug treatments can be more effective than constant-dose monotherapy or combination therapy in vitro. This integrated platform advances organoids models to screen and mirror real patient treatment courses with potential to facilitate treatment decisions for personalized therapy. The use of organoids in personalized medicine is promising but high throughput platforms are needed. Here the authors develop an automated, high-throughput, microfluidic 3D organoid culture system that allows combinatorial and dynamic drug treatments and real-time analysis of organoids.

Subfields: Biomedical Engineering, Oncology

View Paper: https://www.semanticscholar.org/paper/0130050f26c0e4b432907049081bc149757d8a7f